INTRODUCTION
Microbubbles are gas filled microspheres which are approved for diagnostic ultrasound contrast imaging by the FDA. Such bubbles, a few microns in size, are usually filled with an hydrophobic gas and are stabilized by a surfactant (lipid, protein or polymer) shell, to enhance their shelf life and circulation time in blood after injection. Because of the difference in density between the gas core of the microbubble and the surrounding fluid, microbubbles start to oscillate when subjected to high frequency (1-10 MHz) ultrasound. This "cavitation" of microbubbles has been intensively studied by means of high speed optical imaging [1] [2] [3] and can be divided into respectively stable and inertial cavitation. In an ultrasound field with a low acoustical pressure microbubbles are stably cavitating and will oscillate around a given diameter. Inertial cavitation on the other hand occurs at higher acoustical pressures, the movement of the microbubbles becomes more violent which leads to destruction of the microbubbles [4] . This microbubble destruction produces distinct nonlinear acoustic echoes which are very useful in contrast enhanced ultrasound imaging [5] . Cavitation of microbubbles may also induce biological and mechanical effects on the surrounding space which may be particularly useful for drug delivery [6] .
When microbubble collapse occurs in the vicinity of cells it has been shown that plasma membranes are temporarily permeabilized through the formation of transient pores in the cellular membrane, induced by micro-jets and shockwaves produced after microbubble collapse [3, 7] . This phenomenon is called sonoporation [6] . It is believed that sonoporation is strongly dependent on the acoustical properties of the applied ultrasound field [8, 9] . Such transient pores also enhance the uptake of macromolecules in cells [10] . Recent studies show that sonoporation effects may last up to 24 hours after ultrasound treatment [11] . The use of microbubbles in combination with ultrasound may even induce openings in the blood-brain barrier which could be of interest to tackle drug delivery into the brain which currently remains a huge challenge [12, 13] .
Only if the drug molecules are physically located in the vicinity of microbubbles subjected to ultrasound, it is expected that sonoporation will enhance drug uptake by cells. Moreover, as these effects will only occur where and when ultrasound is applied, drug delivery is expected only to happen in the insonated tissue. Hence, for ultrasound targeted drug delivery it is crucial to design microbubbles which can be loaded with drug molecules. Meanwhile a number of concepts for drug loaded microbubbles are under investigation [14] [15] [16] . Basically, microbubbles can be loaded with drugs in three ways: (a) the drug can be incorporated in the microbubble shell [17] , (b) (lipophilic) drugs can be incorporated in an inner oil phase present in the microbubbles [18] or (c) "colloidally drug loaded microbubbles" can be obtained through the attachement of drug containing nanoparticles (like e.g. liposomes) on the microbubbles" surface as reviewed by Bohmer et al. and Lentacker et al [19, 20] .
Independent on the way the microbubbles become loaded with drugs, they should fulfill at least the following requirements: (a) the microbubbles should be loaded with a sufficient amount of drug; (b) the shelf-life of the drug-loaded microbubbles should be long enough and (c) the drug-loaded microbubbles should be designed without the incorporation of toxic or immunogenic substances. We believe that loading the surface of microbubbles with drug containing liposomes is a promising concept for ultrasound guided drug delivery as: (a)more drugs can be loaded on microbubbles compared with other loading strategies, (b) a plethora of knowledge is available on liposomes for drug delivery which can be perfectly used to develop the colloidally loaded microbubble concept and (c) importantly, certain liposomes are safe and even already used in clinical practice.
Recently we succeeded in preparing respectively doxorubicin (DOX)-liposome loaded microbubbles [21] and lipoplex-loaded microbubbles (containing pDNA or siRNA). We showed that in combination with ultrasound, such microbubbles strongly improved both doxorubicin (DOX) cytotoxicity and pDNA [16, 22] and siRNA [23] delivery to cells in vitro. However, the complex microbubble preparation method, the immunogenic nature of the avidin-biotin chemistry used to link the liposomes/lipoplexes to the microbubbles and the successive washing steps, made this material not ideal for easy clinical use. It is clear that the concept of liposome-/lipoplex-loaded microbubbles needs further development and improvement. In this work we faced the challenge to design DOX-liposome loaded lipid shelled microbubbles through the self-assembly of the involved compounds. Importantly, the method we propose involves just a single step and allows to make a sterile material.
As illustrated in Figure 1 and further explained in the results section, to a mixture of phospholipids, so named "functionalized DOX-liposomes" (i.e. DOX-liposomes containing MALEIMIDE functionalized PEG-lipids) and a hydrophobic gas were added. We show that under appropriate conditions these compounds self-assemble into DOX-liposome loaded microbubbles which are responsive to ultrasound and efficiently kill cells. 
Preparation of non-functionalized microbubbles
Preparation of so named "non-functionalized microbubbles" occurred as DOX-liposomes were prepared as described by lentacker et al [21] . 
Preparation of liposome-loaded microbubbles
Liposome-loaded microbubbles were prepared by adding a certain volume of the liposome dispersion to the lipid solution used for the preparation of microbubbles (see above, under 1.1 and 1.2). Liposome-loaded microbubbles were obtained by high-speed shaking of this liposome/lipid mixture in a Capmix™ device. The loading of the microbubbles with (bodipy-containing) liposomes was visualized using a Nikon EZC1 confocal microscope equipped with a 60x lens imaging using the 490 nm excitation light, while fluorescence was detected at 551 nm.
Evaluation of the loading of the microbubbles with liposomes by flow cytometry
How different parameters influence the loading of microbubbles with bodipylabeled liposomes was determined using a flow cytometer (BD FACScalibur, Erembodegem, Belgium). Herefore 300 µl of (bodipy-) liposome-loaded microbubbles were diluted in 300 µl of HEPES buffer. The 488 nm laser of the flow cytometer was used to excite the bubbles while the emitted fluorescence was detected in the 530 nm channel FL1. Results were expressed as mean fluorescence per microbubble using unloaded microbubbles as a blank. For measurements on microbubbles in plasma, platelet poor plasma was obtained by centrifuging whole blood samples first at 300 g for 10 min and subsequently at 3200 g for 10 min. 20 µl of (bodipy-)
liposome-loaded microbubbles were suspended in 150 µl of plasma and diluted with 200 µl Hepes buffer. All the flow cytometry experiments were performed in triplicate and the presented data are the mean values.
Evaluation of the loading of the microbubbles with liposomes by Coulter

Counter measurements
The loading of the microbubbles with liposomes was further studied by the electrical sensing zone method with a Beckman-Coulter Multisizer 4 Coulter Counter. x 10 -4 mmol/ml) and respectively 0, 35, 100 and 200 µl bodipy liposomes into a 2.5 ml chromatography vial, followed by high-speed shaking in the Capmix™ device.
We determined respectively the number of (unloaded and liposome-loaded) microbubbles per mL and the volume of all bubbles present in 1 ml of dispersion (i.e.
"total volume per ml"). The volume of a single microbubble could then be determined by equation (1).
(
The volume increase of a microbubble upon loading with lipsosomes (i.e. "liposome volume per bubble") could be calculated by equation (2) 
All measurements were performed at least in triplicate and results are presented as the mean of three different measurements.
Ultrasound induced DOX-release
The release of doxorubicin from the liposomes was determined by fluorescence measurements. The following samples were prepared for the release experiments.
One ml of lipid solution was mixed with 10 or 20 µl of DOX-liposomes with a DOXconcentration of 0.1 mg/ml and C 4 F 10 gas. After shaking the lipid/lipsome mixture in the Capmix™ device the mixture was diluted with PBS to a final volume of 10 ml and injected in an Opticell TM (Biocrystal, Westerville, OH) plate. This plate was submerged in a water bath (37°C) with an absorbing rubber and subjected to ultrasound during 15 s using the Sonitron device (Artison Corporation, Inola, OK, USA) equipped with a 2 cm ultrasound probe [22, 24] . This probe was used with an ultrasound frequency of 1 MHz with 20 % duty cycle at an ultrasound intensity of 2 W/cm 2 . Subsequently, the fluorescence of each sample was measured in a Wallac envision plate reader (λ exc 500 nm, λ em 550 nm). Each experiment was performed at least in triplicate.
Cell culture and cytotoxicity tests
BLM cells [24] (melanoma cells) were cultured in F12-supplemented Dulbecco"s was added for 4 hours. Subsequently, the sollubilization reagent was added and cells were incubated overnight to allow cell lysis at 37°C. The next day, the absorbance of each plate was measured in an absorbance plate reader at respectively 590 nm (OD 590 ) to determine the formed formazan and at 690 nm (OD 690 ) as a reference. The results of the cytotoxicity measurements are expressed as percentages; the viability of the cells which were only treated with optimem was considered to be 100 %, while the viability of cells exposed to phenol was considered to be 0 %. Experiments were performed at least in triplicate.
Statistical analysis
All data are presented as means +/-one standard deviation. A student"s t-test was performed to determine whether datasets differed significantly. A p-value smaller than 0.05 was regarded significant.
RESULTS
Preparation of liposome-loaded microbubbles by self-assembly
As schematically presented in Figure 1 , to make liposome-loaded microbubbles, to a mixture of the (functionalized) lipids DPPC and DSPE-PEG-SPDP, dissolved in a glycerine-propyleneglycol-water solvent at a concentration below their critical micellar concentration [25] , liposomes containing DSPE-PEG-MALEIMIDE were added. We observed that liposomes dispersed in the lipid solution are stable and can be stored during at least several weeks (data not shown).
Therefore we stored the liposome/lipid dispersion at 4°C in chromatography vials. To "activate" the mixture, which refers to (as formation of liposome loaded microbubbles ( Figure 1C ), the vials" headspaces were filled with perfluorobutane gas and subsequently mixed with a high speed shaking-device (Capmix™ or Vialmix™). The
Capmix™ disperses the lipophilic perfluorobutane in the lipid solution. Hence, the hydrophobic tales of the dissolved lipids interact with the dispersed gas and stabilize the gas bubbles formed. Because functionalized (SPDP-) PEG-lipids were used which can interact with the functionalized (MALEIMIDE-)PEG-lipids of the liposomes ( Figure 1D ), liposome-loaded microbubbles were spontaneously formed during this process as can be seen in the confocal image in Figure 2B and its corresponding transmission image (Figure 2A ) clearly show bodipy-labeled liposomes at the surface of the microbubbles. 
Improving the liposome-loading of the microbubbles
Clearly, the more liposomes could be loaded onto the microbubble shell, the more drug could be released when the microbubble collapses. In a next step we evaluated whether the microbubble loading could be increased by using higher amounts of DSPE-PEG-SPDP lipids in the microbubble shell. We evaluated the amount of liposomes loaded per bubble through the use of bodipy-labeled liposomes and quantifying the fluorescence of the bodipy-liposome-loaded microbubbles through flow cytometry. Figure 3A clearly shows that the mean fluorescence per bubble increases upon (a) adding more liposomes to the mixture and (b) using higher amounts of DSPE-PEG-SPDP in the lipid mixture. Figure 3B shows Coulter Counter measurements on the corresponding bubbles and clearly indicates that upon using 35% DSPE-PEG-SPDP the microbubbles become substantially larger which explains the increased loading capacity of these microbubbles as more surface space per bubble is available. We noticed that it is possible to incorporate even higher amounts of DSPE-PEG-SPDP-lipids in the bubbles, however, the resulting microbubbles were unstable. Hence, we concluded that the use of a 35% molar ratio of DSPE-PEG-SPDP-lipids is optimal for liposome loading. 
Behavior of liposome-loaded microbubbles in plasma
Clearly, successful ultrasound triggered drug release assumes that the microbubbles keep the drug as long as ultrasound energy is not applied. To judge whether liposome-loaded microbubbles remain stable once injected in plasma and do not release drug due to interactions with plasma components, we performed flow cytometry measurements on microbubbles loaded with bodipy-liposomes dispersed in human platelet poor plasma (Figure 4 ). We could not observe significant differences in the fluorescence of liposome-loaded microbubbles dispersed in respectively plasma and buffer indicating that liposome-loaded microbubbles remain stable in plasma. Hence we predict that the liposomes will remain bound to the bubbles after injection in the bloodstream, at least as long as they are not exposed to ultrasound. 
Aspecific interactions between the liposomes and the microbubbles
Subsequently we evaluated whether liposomes can stick (i.e. become aspecifically bound) to the microbubbles. Therefore we prepared microbubbles with DSPE-MPEG lipids without functional end groups, thereby avoiding covalent binding. Figure 5A shows the fluorescence of non-functionalized microbubbles exposed to bodipy-liposomes, as measured through flow cytometry. Clearly, liposomes bind aspecifically to the microbubbles. However, as could be expected, liposome loading of the microbubbles through covalent interactions enables significantly higher loading, which is of interest for use in drug delivery. One could speculate about the nature of the aspecific interactions between the liposomes and microbubbles. As schematically illustrated in Figure 5B , entanglements between PEG-chains on the liposomes and microbubbles may contribute to this phenomenon. 
Coulter Counter measurements gain further insight in the amount of liposomes loaded
Although flow cytometry experiments revealed clear information on the loading of the microbubbles with liposomes, it remained impossible to estimate the number of liposomes loaded per microbubble. This information is of interest as it defines the drug dose which can be loaded on the microbubbles" surface. We reasoned that measuring the increase in volume of a microbubble upon loading it with liposomes (defined as "liposome volume per bubble") in equation (2)) could give us valuable information. Dividing this "liposome volume per bubble" by the volume of one liposome allows us to estimate this number. Figure 6 shows the results of these experiments. For microbubbles with covalently attached liposomes we estimated that between 600 and 1300 liposomes can be loaded on the microbubbles" surface, which is significantly higher than the number which can be loaded through aspecific interactions. These data confirm the results obtained by Klibanov et al. [26] where is
claimed that approximately 2000 liposomes with a diameter of 0.1µm can be bound to one bubble with a diameter of 2.5µm. However the number of 600-1300 liposomes per bubble is based on a volumetric measurement with the Coulter Counter.
Interestingly, the results obtained through Coulter Counter measurements confirm the data observed in Figure 5A which were obtained through flow cytometry. Fluorescence intensity of DOX (expressed as relative light units (RLU)) significantly increases when liposome loaded microbubbles are subjected to ultrasound, indicating that DOX leaks out of destroyed liposomes after ultrasound treatment.
Biological efficacy of DOX-loaded liposome bubbles treated with ultrasound
In a next step we evaluated the tumor cell killing efficacy of DOX-liposome loaded microbubbles. Figure 8B shows the results of an in vitro cytotoxicity assay using different cell killing strategies. Clearly, ultrasound treatment of DOX-liposome loaded microbubbles (white bars) results in a significantly stronger killing of the cells.
The x-axes in Figure 8B indicates the concentration of DOX in the Opticells™. Note that a higher DOX concentration was obtained through the use of microbubbles which were more loaded with DOX-liposomes (i.e. the number of DOX-liposome loaded microbubbles per Opticell™ was constant). Clearly, the "heavier" the microbubbles are loaded with DOX-liposomes the more cytotoxic they are.
Importantly, without ultrasound DOX-liposome loaded microbubbles do not kill cells (dark gray bars in Figure 8B ). As the DOX-liposome loaded microbubbles are not cytotoxic as long as they are not subjected to ultrasound, we suggest that such bubbles in combination with ultrasound may allow targeted release of DOX. We would like to note that, as the cytotoxicity experiments were done on a cell monolayer, cells were occasionally (physically) removed from this layer due to the ultrasound energy or the microbubbles treatment itself. This could induce false positive results in the cytotoxity experiments, although microbubble concentrations are used that induced a minimal cell displacement as verified microscopy (data not shown). The bars in Figure 8A show that at microbubble concentrations used in the experiments there was no significant killing of the cells due to the microbubble destruction itself; the observed cytotoxicity was similar to that observed with the blank (optimem). 
Can dose reduction be achieved with DOX-liposome loaded microbubbles?
In the experiments in Figure 8 the DOX-liposome loaded microbubble dispersions did still contain an amount of free DOX-liposomes as it was experimentally difficult to separate free liposomes from the microbubbles. We were especially interested in the cell killing properties of the DOX-lipsosome loaded microbubbles themselves. We described above that between 600 and 1300 liposomes can be bound per microbubble. Therefore we prepared a DOX-liposome microbubble dispersion using an amount of DOX-liposomes which is expected to which would allow such a high DOX dosing is highly likely impossible unless really high amounts of bubbles (in the order of 1 x 10 13 bubbles/ml) could be injected.
However, considering the targeted and more efficient delivery of DOX when ultrasound and DOX-liposome loaded bubbles are used, we believe that such high DOX-doses might be no longer necessary, which may also reduce the severe sideeffects of DOX-therapy in particular and chemotherapy in general.
Since apparati suitable for in vivo ultrasound assisted drug delivery that are able to deliver ultrasound into a focal spot deep into the tissue are allready under full development [29] , the clinical evaluation of the drug-loaded microbubbles reported in this paper will smoothly move on and hopefully make it from bench to bedside.
CONCLUSIONS
This paper showed that that DOX-liposome loaded microbubbles can be obtainbed through self-assembly of (functionalized) phospholipids, drug-loaded liposomes and perfluorobutane gas. Importantly, this single step process results in a material which meets all criteria for clinical applicability: (a) no immunogenic compounds are used;
(b) sterilization can easily be achieved through straightforward techniques and (c) adequate amounts of liposomes can be stabily loaded on the surface of the bubbles. showed a significantly stronger killing of cancer cells. It is our opinion that the DOXliposome loaded microbubbles described in this paper provide an opportunity for ultrasound targeted cancer therapy.
